These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 33767400)
1. Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study. Bento L; Gutiérrez A; Novelli S; Montoro J; Piñana JL; López-Corral L; Cabrero M; Martín-Sancho A; Gutiérrez-García G; Ortiz-Moscovich M; Bastos-Oreiro M; Dorado N; Pérez A; Hernani R; Ferrà C; Parody R; García-Cadenas I; Herrera P; Rodríguez G; Rodríguez N; Martín C; Yáñez L; Zanabili J; Varela MR; López-Godino O; Heras I; Español I; Martínez C; Pérez-Simón JA; Solano C; Sureda A; Sierra J; Sampol A; Caballero D; Bone Marrow Transplant; 2021 Aug; 56(8):1919-1928. PubMed ID: 33767400 [TBL] [Abstract][Full Text] [Related]
2. R-BEAM versus Reduced-Intensity Conditioning Regimens in Patients Undergoing Allogeneic Stem Cell Transplantation for Relapsed Refractory Diffuse Large B Cell Lymphoma. Modi D; Kim S; Surapaneni M; Ayash L; Alavi A; Ratanatharathorn V; Deol A; Uberti JP Biol Blood Marrow Transplant; 2020 Apr; 26(4):683-690. PubMed ID: 31682979 [TBL] [Abstract][Full Text] [Related]
3. Hematopoietic stem cell transplantation for diffuse large B-cell lymphoma having 8q24/MYC rearrangement in Japan. Takahashi T; Suzuki R; Yamamoto G; Nakazawa H; Kurosawa M; Kobayashi T; Okada M; Akasaka T; Kim SW; Fukuda T; Ichinohe T; Atsuta Y; Suzumiya J Hematol Oncol; 2021 Feb; 39(1):66-74. PubMed ID: 32979280 [TBL] [Abstract][Full Text] [Related]
4. Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience. Gutierrez A; Bento L; Novelli S; Martin A; Gutierrez G; Queralt Salas M; Bastos-Oreiro M; Perez A; Hernani R; Cruz Viguria M; Lopez-Godino O; Montoro J; Piñana JL; Ferra C; Parody R; Martin C; Español I; Yañez L; Rodriguez G; Zanabili J; Herrera P; Varela MR; Sampol A; Solano C; Caballero D; On Behalf Of The Grupo Español de Trasplante de Progenitores Hematopoyéticos Geth And Grupo Español de Linfoma Y Trasplante Autólogo Geltamo Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681653 [TBL] [Abstract][Full Text] [Related]
5. Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy in Large B Cell Lymphoma. Fried S; Shouval R; Walji M; Flynn JR; Yerushalmi R; Shem-Tov N; Danylesko I; Tomas AA; Fein JA; Devlin SM; Sauter CS; Shah GL; Kedmi M; Jacoby E; Shargian L; Raanani P; Yeshurun M; Perales MA; Nagler A; Avigdor A; Shimoni A Transplant Cell Ther; 2023 Feb; 29(2):99-107. PubMed ID: 36343892 [TBL] [Abstract][Full Text] [Related]
6. Allogeneic stem cell transplantation in patients with de novo diffuse large B-cell lymphoma who experienced relapse or progression after autologous stem cell transplantation: a Korea-Japan collaborative study. Kim JW; Kim SW; Tada K; Fukuda T; Lee JH; Lee JJ; Kwon JH; Bang SM; Kim I; Yoon SS; Lee JS; Park S Ann Hematol; 2014 Aug; 93(8):1345-51. PubMed ID: 24633661 [TBL] [Abstract][Full Text] [Related]
13. Impact of Reduced-Intensity Conditioning Regimens on Outcomes in Diffuse Large B Cell Lymphoma Undergoing Allogeneic Transplantation. Epperla N; Ahn KW; Khanal M; Litovich C; Ahmed S; Ghosh N; Fenske TS; Kharfan-Dabaja MA; Sureda A; Hamadani M Transplant Cell Ther; 2021 Jan; 27(1):58-66. PubMed ID: 32956819 [TBL] [Abstract][Full Text] [Related]
14. Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience. Rezvani AR; Norasetthada L; Gooley T; Sorror M; Bouvier ME; Sahebi F; Agura E; Chauncey T; Maziarz RT; Maris M; Shizuru J; Bruno B; Bredeson C; Lange T; Yeager A; Sandmaier BM; Storb RF; Maloney DG Br J Haematol; 2008 Nov; 143(3):395-403. PubMed ID: 18759762 [TBL] [Abstract][Full Text] [Related]
15. Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Genadieva-Stavrik S; Boumendil A; Dreger P; Peggs K; Briones J; Corradini P; Bacigalupo A; Socié G; Bonifazi F; Finel H; Velardi A; Potter M; Bruno B; Castagna L; Malladi R; Russell N; Sureda A Ann Oncol; 2016 Dec; 27(12):2251-2257. PubMed ID: 28007754 [TBL] [Abstract][Full Text] [Related]
16. Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Sahebi F; Eikema DJ; Koster L; Kroger N; Meijer E; van Doesum JA; Rovira M; Koc Y; Angelucci E; Blaise D; Sammassimo S; McDonald A; Arroyo CH; Sanchez JF; Forcade E; Castagna L; Stölzel F; Sanz J; Tischer J; Ciceri F; Valcarcel D; Proia A; Hayden PJ; Beksac M; Yakoub-Agha I; Schönland S Transplant Cell Ther; 2021 Dec; 27(12):999.e1-999.e10. PubMed ID: 34543768 [TBL] [Abstract][Full Text] [Related]
17. Nonmyeloablative Conditioning Regimen before T Cell Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Advanced Hodgkin and Non-Hodgkin Lymphomas. Montes de Oca C; Castagna L; De Philippis C; Bramanti S; Schiano JM; Pagliardini T; Collignon A; Harbi S; Mariotti J; Granata A; Maisano V; Furst S; Legrand F; Chabannon C; Carlo-Stella C; Santoro A; Blaise D; Devillier R Biol Blood Marrow Transplant; 2020 Dec; 26(12):2299-2305. PubMed ID: 32822845 [TBL] [Abstract][Full Text] [Related]
18. Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agents. Faisal MS; Hanel W; Voorhees T; Li R; Huang Y; Khan A; Bond D; Sawalha Y; Reneau J; Alinari L; Baiocchi R; Christian B; Maddocks K; Efebera Y; Penza S; Saad A; Brammer J; DeLima M; Jaglowski S; Epperla N Cancer Med; 2023 Apr; 12(7):8228-8237. PubMed ID: 36653918 [TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes of allogeneic stem cell transplantation for relapsed or refractory follicular lymphoma: a retrospective analysis by the Fukuoka Blood and Marrow Transplantation Group. Ito Y; Miyamoto T; Kamimura T; Takase K; Henzan H; Sugio Y; Kato K; Ohno Y; Eto T; Teshima T; Akashi K Int J Hematol; 2013 Oct; 98(4):463-71. PubMed ID: 24043582 [TBL] [Abstract][Full Text] [Related]
20. Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire. Sirvent A; Dhedin N; Michallet M; Mounier N; Faucher C; Yakoub-Agha I; Mohty M; Robin M; Tabrizi R; Clement L; Bilger K; Larosa F; Contentin N; Huyn A; François S; Bulabois CE; Ceballos P; Bourrhis JH; Buzyn A; Cornillon J; Guillerm G; de Revel T; Bay JO; Guilhot F; Milpied N Biol Blood Marrow Transplant; 2010 Jan; 16(1):78-85. PubMed ID: 19744569 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]